Iron infusion: when it is indicated, which tests it requires and how soon the effect shows

Intravenous iron is often sought as a quick fix for tiredness. It is a misunderstanding worth correcting from the outset: intravenous iron is a treatment, not a supplement. It is given on the basis of blood tests confirming iron deficiency, and its effect on iron-deficiency anaemia is not felt on the day it is given. Below: what the data say and how we work in practice.

Iron deficiency is not diagnosed from symptoms

Tiredness, pallor, breathlessness on exertion, hair loss or difficulty concentrating are real, but non-specific — they occur in a large number of other conditions. Iron deficiency is diagnosed exclusively through laboratory tests.

We ask for three, and a fourth depends on the context:

• Serum ferritin — reflects the body's iron stores. It is the indicator with the best diagnostic value, but it has an interpretation limit, detailed below.
• Serum iron — the circulating iron.
• Full blood count — shows whether the deficiency has already progressed to iron-deficiency anaemia and, through the red cell indices (MCV, MCH — listed as VEM and HEM on Romanian lab reports), points the diagnosis towards a hypochromic microcytic anaemia.
• C-reactive protein (CRP) — whenever an inflammatory process is suspected.

Why we also ask for C-reactive protein

This is where the most common interpretation error arises. Ferritin is an acute-phase reactant: its values rise with inflammation, infection or after intense exertion. As a result, a patient with genuine iron deficiency can have a ferritin that looks within normal limits if they also have an inflammatory process.

The World Health Organization guideline on the use of ferritin explicitly recognises the problem and recommends different thresholds: below 15 µg/L in healthy adults, but below 70 µg/L in adults with inflammation or infection, precisely because the value is falsely raised. The same guideline recommends assessing inflammation markers together with ferritin.

In practice: without CRP, a ferritin of 40 µg/L can be wrongly read as normal in a patient who in fact needs treatment. That is why we do not interpret ferritin in isolation.

When the intravenous route makes sense and when it does not

For most people with iron deficiency, oral supplementation is the first option — it is cheap, it works and it involves no procedure. We do not replace it without reason.

The intravenous route becomes justified in specific situations:

• documented digestive intolerance to oral preparations (nausea, upper abdominal pain, constipation that make it impossible to stick with treatment);
• malabsorption syndromes — inflammatory bowel disease, coeliac disease, a history of bariatric surgery;
• chronic losses — heavy periods, gastrointestinal bleeding — that exceed what the oral route can make up;
• the need to correct the deficiency within a defined time, for example before surgery;
• severe deficiency, where oral repletion would take an unacceptably long time.

If none of these applies, we will tell you that you do not need an infusion. It happens often.

What we give and how long it takes

We work with two preparations, chosen according to the size of the deficiency:

• Ferric carboxymaltose (Ferinject), 500 mg of iron — about 2.5 hours, infusion and observation.
• Iron sucrose (Venofer), 200 mg of iron — about 1.5 hours, infusion and observation.

These durations are the real time spent at the clinic, not just the drip time. The brand names are mentioned here as clinical information — both are prescription-only medicines, and the choice between them is made by the doctor at the assessment, not by the patient.

Iron preparations: what sets them apart

The names most often mentioned in Romania are Ferinject, Venofer, Monofer and Ferrum Hausmann. They are often compared with one another, although they are not all the same type of product — the first and most important distinction is the route of administration.

Ferrum Hausmann is not an infusion. In Romania it is sold in oral forms — syrup, drops, oral solution — and treatment runs over months, not sessions. It appears here because it is searched for alongside the others, and confusing an oral preparation with an intravenous one leads to wrong expectations in both directions. At Synerva we give the first two. Monofer is mentioned because it comes up constantly in patients' comparisons and because its difference from carboxymaltose is documented — see the section on phosphate. We do not give it. What this means in practice. Ferric carboxymaltose allows a larger amount of iron in a single session, so it corrects a significant deficiency with fewer visits. Iron sucrose delivers less iron per session, so it usually requires more administrations, but it does not have the phosphate signal described below.

The choice is made at the assessment, according to the size of the deficiency, the urgency of correcting it, tolerance and any associated conditions. It is not a patient preference.

How much an iron infusion costs

The 500 mg protocol costs 1,100 RON and the 200 mg protocol costs 600 RON. Both include the medical assessment, sterile materials and monitoring throughout the administration — there are no costs added later. The full list is on the prices page.

One thing worth knowing when you compare: the real cost of correcting a deficiency is not the price of one session but of the whole regimen. A significant deficiency corrected with 200 mg per session requires more visits, so the right comparison is based on the total amount of iron needed, which is set at the assessment.

Both are given only at the clinic. We do not give iron infusions at home, even though our other protocols can be given at home — the reason is below and has nothing to do with logistics.

Safety: why it is done only in an equipped setting

All intravenous iron preparations can cause hypersensitivity reactions, and these can be severe. In 2013, the European Medicines Agency completed a review of the whole class and established that intravenous iron must be given only where staff trained to recognise and treat an anaphylactic reaction are present, with resuscitation equipment immediately available.

The same review did away with an old practice: a test dose is no longer recommended, because there are data showing that an allergic reaction can occur in a patient who did not react to the test dose. The practical conclusion is that caution applies to every administration, including in patients who have tolerated previous infusions.

That is why, throughout the administration, there is continuous monitoring — blood pressure, oxygen saturation, pulse and ECG — and why you stay at the clinic after the infusion has finished too. The protocol is coordinated by an intensive care physician (anaesthesia & intensive care), the specialty that deals with exactly this kind of situation every day. A home, however well equipped the nurse, is not the right setting.

Phosphate: an honest note about Ferinject

There is a difference between the two preparations that we would rather state than skirt around.

Ferric carboxymaltose (Ferinject) is associated with a fall in serum phosphate, usually transient and without symptoms, but sometimes severe. Two randomised trials published in JAMA in 2020 compared ferric carboxymaltose directly with ferric derisomaltose and found hypophosphataemia in 74.4% of patients treated with carboxymaltose, compared with 8.0% in the comparator arm — so it is not a class effect of parenteral iron but one specific to this preparation. The ferric derisomaltose in the trial is the active substance in Monofer — hence the difference in the table above.

A pooled analysis of 45 trials with ferric carboxymaltose shows that the lowest phosphate values occur about two weeks after administration and return to normal, in most cases, by 12 weeks.

What this means in practice: with a single administration, in a patient without risk factors, the practical risk is low. With repeated doses or long-term treatment, we monitor serum phosphate, in line with the regulators' recommendations. Please let us know if, after the infusion, you develop tiredness that keeps getting worse, together with muscle aches or bone pain — these are the signs that call for reassessment.

How soon the effect shows

This is the part that most often goes against expectations.

You do not leave the clinic with more energy. The iron given has to be built into newly formed red blood cells, and making red blood cells takes time. The first biological sign of response is a rise in reticulocytes, about 5–10 days after starting treatment. The effects on correcting anaemia show at least two weeks after administration, and haemoglobin normalises gradually, over several weeks.

Anyone who promises you a result you can feel the next day is selling you something other than treatment for iron deficiency.

When we do not give it

• In pregnancy and breastfeeding, without an indication and supervision from the treating doctor.
• In known hypersensitivity to the preparation or to any component of the solution.
• In active acute infections.
• When laboratory tests do not support a diagnosis of iron deficiency — however suggestive the symptoms.
• When there is an uninvestigated source of loss. Iron corrects the consequence, not the cause: if the loss continues, the deficiency comes back. In these situations the right course is to investigate the cause, not to repeat the infusion.

What we do at SYNERVA

We start with the blood tests. If you already have them, bring them to the appointment; if not, we will tell you exactly what to do. At the assessment we establish whether intravenous iron is indicated, which of the two preparations suits you and at what dose. If the answer is that oral treatment is enough, that is what you get — and it is the right answer more often than you might think.

You can book an assessment or write to us on WhatsApp.

---

Sources

European Medicines Agency — Intravenous iron-containing medicinal products: referral (Article 31 review, 2013): the requirement for trained staff and resuscitation equipment; the end of the test dose.

World Health Organization — WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations (2020): ferritin thresholds and the adjustment when inflammation is present.

Wolf M. et al. — Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials, JAMA, 2020 (the PHOSPHARE-IDA trials).

A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose, Journal of Clinical Medicine, 2020: how serum phosphate changes over time.

Therapeutic Goods Administration — Ferric carboxymaltose and low blood phosphorous: recommendations on phosphate monitoring and warning signs.

Iron Deficiency Anemia Treatment & Management, Medscape: the timeline of the reticulocyte response to iron treatment.

MONOFERRIC (ferric derisomaltose) — prescribing information, DailyMed / FDA: the single dose of 1000 mg, or 20 mg/kg, with a maximum of 1500 mg.

Ferrum Hausmann syrup — leaflet (Romanian): the oral form, composition and the 3–5-month length of treatment.

This article is for information only and does not replace a medical consultation. The decision to give treatment rests with the doctor, after assessing each case individually.